University Hospital Maastricht

Landmark Clinical Trials of 2024: Promising Advances in Cancer, Malaria, and Genetic Diseases

a year ago

• AstraZeneca's trastuzumab deruxtecan shows a 73.3% intracranial response rate in breast cancer patients with brain metastases, offering a potential new treatment option. • Oxford University's malaria vaccine, R21/Matrix-M, demonstrates a 78% efficacy rate in young African children, marking a significant improvement over existing vaccines. • Verve Therapeutics' VERVE-101/VERVE-102 utilizes in vivo base-editing to deactivate the PCSK9 gene mutation, potentially providing a one-time treatment for high cholesterol. • A Netherlands Cancer Institute study suggests that neoadjuvant ipilimumab and nivolumab may eliminate the need for surgery in stage III melanoma patients, with a 72% positive response.